Hyperacute toxicity with combination ipilimumab (ipi) and anti-PD1 immunotherapy.
Year: 2018
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Helen Clare Dearden, Lewis Au, Daniel Ying Wang, Lisa Zimmer, Zeynep Eroglu, Jessica Louise Smith, Marcello Curvietto, Chloe Khoo, Victoria Atkinson, Serigne Lo, Alexander Guminski, Georgina V. Long, Shahneen Kaur Sandhu, Paolo Antonio Ascierto, Matteo S. Carlino, Douglas Buckner Johnson, James M. G. Larkin, Alexander M. Menzies
Institutions: Melanoma Institute Australia, Royal Marsden NHS Foundation Trust, Vanderbilt University Medical Center, Essen University Hospital, University of Duisburg-Essen, Moffitt Cancer Center, Westmead Hospital, Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", Peter MacCallum Cancer Centre, The University of Queensland, Greenslopes Private Hospital, Princess Alexandra Hospital, The University of Sydney, Royal North Shore Hospital, Royal Marsden Hospital
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2890224213